News
RETA
39.21
+2.64%
1.01
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
Benzinga · 1d ago
Analyst Ratings for Reata Pharmaceuticals
Benzinga · 1d ago
Goldman Sachs Maintains Buy on Reata Pharmaceuticals, Raises Price Target to $115
Benzinga · 2d ago
Goldman Sachs Adjusts Price Target on Reata Pharmaceuticals to $115 From $86, Maintains Buy Rating
Goldman Sachs Adjusts Price Target on Reata Pharmaceuticals to $115 From $86, Maintains Buy Rating
MT Newswires · 2d ago
Reata Pharmaceuticals, Inc.'s stock is down 14%, but insiders still have about US$163k in profit after buying earlier this year
Insiders who purchased Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) shares in the past 12 months are unlikely to be...
Simply Wall St. · 11/22 14:20
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
PLANO, Texas, November 10, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that management will participate in the Guggenheim 2022 Immunology & Neurology Confer...
Business Wire · 11/10 21:42
Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates
Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.
Zacks · 11/09 15:55
Goldman Sachs Maintains Buy on Reata Pharmaceuticals, Raises Price Target to $86
Benzinga · 11/09 14:57
Planet Fitness To Surge Over 25%? Plus Morgan Stanley Cuts PT On This Stock By 50%
Benzinga · 11/09 13:44
Citigroup Maintains Buy on Reata Pharmaceuticals, Raises Price Target to $53
Benzinga · 11/09 12:52
Barclays Maintains Overweight on Reata Pharmaceuticals, Raises Price Target to $50
Benzinga · 11/09 12:35
--Goldman Sachs Adjusts Price Target on Reata Pharmaceuticals to $86 From $76, Maintains Buy Rating
--Goldman Sachs Adjusts Price Target on Reata Pharmaceuticals to $86 From $76, Maintains Buy Rating
MT Newswires · 11/09 11:55
--Citigroup Adjusts Price Target on Reata Pharmaceuticals to $53 From $51, Maintains Buy Rating
--Citigroup Adjusts Price Target on Reata Pharmaceuticals to $53 From $51, Maintains Buy Rating
MT Newswires · 11/09 11:03
--Barclays Adjusts Price Target on Reata Pharmaceuticals to $50 From $43, Maintains Overweight Rating
--Barclays Adjusts Price Target on Reata Pharmaceuticals to $50 From $43, Maintains Overweight Rating
MT Newswires · 11/09 10:43
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Benzinga · 11/09 10:08
DuPont, Expeditors International, Planet Fitness And Other Big Gainers From Tuesday
Benzinga · 11/09 07:53
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 11/08 17:51
Reata rises 15% as omaveloxolone moves ahead in FDA review process; plans EU filing
Seekingalpha · 11/08 17:31
IceCure, Allakos top healthcare gainers; NanoString, R1 RCM lead losers' pack
Seekingalpha · 11/08 15:01
Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.09% and 62.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 12:55
More
Webull provides a variety of real-time RETA stock news. You can receive the latest news about Reata Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About RETA
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. It is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.